Sigachi Industries Ltd. Share Price

HDFC MF BUYS 3.19% STAKE IN ENTERO HEALTHCARE SOLUTIONS

HDFC Mutual Fund acquired a 3.19% stake in Entero Healthcare Solutions from Prasid Uno Family Trust through open-market transactions on September 18, even as shares of the healthcare products distribution company gained 3.94% to close at ₹1,732.30 on the NSE. According to block deal data, HDFC Mutual Fund purchased 13.9 lakh shares of Entero Healthcare Solutions, representing 3.19% of the company’s paid-up equity, for ₹235.6 crore. The shares were bought at ₹1,695 apiece. Public shareholder Surbhi Singh, through Prasid Uno Family Trust, was the seller in the transaction. The trust serves as the family investment vehicle of Medlife co-founder Tushar Kumar. Following Friday’s transaction, the trust has sold 32.18 lakh shares, or a 7.39% stake, in Entero Healthcare Solutions during the September quarter. This compares with its 10.45% holding, equivalent to 45.5 lakh shares, as of June 2026. Meanwhile, Boston-based State Street Global Advisors, through the SPDR Portfolio Emerging Markets ETF, sold 37.32 lakh shares, representing a 0.97% stake, in pharmaceutical company Sigachi Industries for ₹11.13 crore. The shares were sold at ₹29.83 apiece. Sigachi Industries ended 0.92% higher at ₹29.60 on Friday after retreating sharply from an intraday high of ₹32.15, with robust trading volumes recorded during the session.

See More

Q3 Earnings Update – February 14:

Industries, , & 461 Others

Q3FY26 Results : A total of 465 companies are set to unveil their October–December quarter earnings on February 14. Key names include

Industries, , , L, , Contracts India, and Industries. In addition, several other firms are expected to report their third-quarter performance today, including , , , , , , , Petroleum India, and ies. These announcements will provide insights into corporate performance for Q3FY26 and are likely to influence market sentiment. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

See More

Sigachi Industries Ltd — Fundamental Overview

Sigachi Industries is a leading manufacturer of pharmaceutical excipients, especially Microcrystalline Cellulose (MCC), which is widely used in tablet and capsule formulations as a binder and filler. The company has expanded from excipients into APIs, specialty chemicals, and contract manufacturing, which helps reduce dependence on a single product line. It operates multiple plants across India with international quality approvals that enable global exports to regulated pharma markets. Their portfolio caters to pharmaceuticals, nutraceuticals, food ingredients, and cosmetics, giving the business a broader end-market footprint. Financially, Sigachi has been growing at a strong pace with healthy revenue and profit growth over the past few years. Operating margins have generally remained steady thanks to efficiency improvements and product mix, though raw-material and power cost volatility can temporarily affect profitability. Cash flow trends have been somewhat inconsistent due to heavy capital expenditure for expansion projects and working-capital requirements, meaning profits don’t always convert smoothly into free cash. The company’s strengths include its scale in MCC manufacturing, diversified customer base across multiple countries, and increasing focus on value-added offerings like co-processed excipients and coatings. Its positioning benefits from global pharma growth and the shift toward outsourcing of ingredient manufacturing from regulated markets to cost-competitive suppliers like India. However, execution risk is real — regulatory compliance, operational reliability, international demand swings, and cost inflation can introduce volatility. Overall, Sigachi offers a promising growth story in the pharma-ingredients supply chain but with noticeable risk elements typical of mid-cap specialty-chemical companies. It is better suited for investors with a medium-to-long-term view who can tolerate fluctuations in margins and cash flow.

See More